TABLE 1.
Description of the patients enrolled in the study
| Patient | Age (yr) | Gender | HIV viral load (copies/ml) |
CD4 count (mm3) |
Yr of diagnosis |
ART regimen |
|---|---|---|---|---|---|---|
| 1 | 51 | M | Undetectable | 1,214 | 2008 | Epzicom, atazanavir/ritonavir |
| 2 | 59 | M | Undetectable | 766 | 2006 | Darunavir, dolutegravir, truvada |
| 4 | 46 | M | Undetectable | 153 | 2011 | Elvitegravir, tonofovir, emtricitabine, ALA |
| 5 | 63 | M | <20 | 790 | 2008 | Efavirenz, emtricitabine, tenofovir |
| 6 | 54 | M | <20 | 698 | 2008 | Abacavir, dolutegravir, lamivudine |
| 8 | 58 | M | <20 | 916 | 2014 | Abacavir, lamivudine |
| 9 | 66 | M | <20 | 417 | 2011 | Efavirenz, emtricitabine, tenofovir |
| 10 | 63 | M | <20 | 445 | 2008 | Truvada, emtricitabine, tenofovir |
| 11 | 60 | M | 64 | 184 | 2011 | Truvada, emtricitabine, tenofovir |
| 12 | 51 | M | <20 | 441 | 2005 | Nevirapine, lamivudine, and azidovudin |
| 13 | 66 | M | 68 | 288 | 1989 | Abacavir, dolutegravir, lamivudine |
| 14 | 46 | M | <20 | 514 | 2015 | Emtricitabine, rilpivirine, tenofovir, ALA |
| 15 | 52 | M | <20 | 1,191 | 2008 | Ritonavir, atazanavir |
| 16 | 52 | M | 1927 | 148 | 2008 | Ritonavir, darunavir |
| 17 | 62 | M | <20 | 430 | 1999 | Truvada, maraviroc |
| 19 | 45 | M | Undetectable | 880 | 1994 | Atazanavir, ritonavir |
| 20 | 44 | M | <20 | 929 | 2012 | Emtricitabine, rilpivirine, tenofovir, ALA |
| 21 | 47 | M | 93 | 1,645 | 1999 | Lopinavir, ritonavir |
| 22 | 49 | F | <20 | 904 | 2006 | Abacabir, dolutegravir |